847.978.0606 info@optivara.com

Case Study:

StratMap in the Real World

Strategic plans and decisions are often based on historical data and past experience. But in the rapidly evolving healthcare environment, improved methods and insights are essential if you are to adapt and be competitive. StratMap empowers your decision makers as it collects, organizes, and synthesizes information on technologies, trends, competitors and potentially disruptive changes.

learn more

Preface

Following is a Case Study conducted by Optivara and Giles & Associates Consultancy demonstrating how StratMap guided a client through the “Future Landscape of Oncology” as part of its 5-year strategic planning process.

This multinational biopharma has a robust pipeline of Oncology products in development. Information was gathered from a broad scan of secondary data sources, then validated and refined by our Expert Oncology Panel.

Viewed within the context of Key Trends identified by StratMap, the company was able vet their R&D portfolio, inform their business development targets, and identify opportunities they could develop on their own. Incorporating these new insights through team planning, the company effectively refined its strategic focus, commercial pre-launch plans, internal R&D priorities and business development initiatives.

Preparing for Oncology’s Future

No therapeutic area exemplifies the changes occurring in the global healthcare market more than Oncology. With 900+ new inventions in research and development in 2014, and twice as many FDA-designated “Breakthrough” innovations as any other therapeutic area, oncology is fully expected to be the fastest growing therapeutic segment.

Whether you’re viewing the future market from a device, biopharmaceutical, or diagnostics perspective, successful participation demands a full understanding of how oncology research, product development, and patient care is being transformed.

So how do companies prepare for a future state that will surely be different than today? We employ StratMap.

StratMap is a content-rich Knowledge Management solution that facilitates envisioning the future and planning for it. StratMap allows us to consider a five-and ten-year time horizon and effectively anticipate the major Change Drivers, Key Trends, Indicators, Opportunities, and Risks.

Oncology projected CAGR

Oncology Market Transformation

  • Given the vast quantities of information available today – via the internet, through proprietary sources, or even housed on individual computers – it is a major challenge to synthesize and determine not only what is relevant today, but what will be significant tomorrow.
  • In Oncology, four core Change Drivers are influencing the future state and requirements for success. The StratMap framework objectively filtered and organized all relevant information, and identified the major trends associated with each driver of change.
  • Trends that are being adopted today, and those likely to emerge, were mapped over the next 10-years and supported with easily accessible reference sources for ongoing review and updates.
Oncology Market Transformation

icon

Key Driver of Change

Biomedical breakthroughs and novel therapeutics

Pathways to innovation

Over the next decade, the oncology market will heavily leverage advances in omics information and personalized therapies. Through targeting of highly selective patient populations, manufacturers can maximize patient and payer cost benefit, and minimize clinical risk.

The biological information within any unique cancer specimen will be transformed into digital information more rapidly and cost efficiently. It will be cataloged and compared with all previously annotated tumor specimens to develop and refine molecularly-based cancer subtypes. As subtypes are better characterized, patient segments will be narrowed and more sharply defined.

  • Model biological systems will determine ex-vivo tumor sensitivity and resistance to available therapies, allowing selection of the most efficacious and well-tolerated options.
  • Treatment combinations will be tailored to the individual patient tumor and host molecular profile.
  • Increasingly, gene and epigenetic therapeutics will correct germlines and, where possible, somatic causal and predisposing genomic mutations or modifications.
  • Prognostic, precision, low toxicity and combination therapies will all become the norm.

icon

Key Driver of Change

Innovative approaches to rapid trial design and regulatory approval

Pathways to commercialization

Thanks to biomedical science advances, mechanisms of action are now well understood, and this specificity has prompted researchers to move past traditional randomized controlled clinical trials (RCTs).

  • Demonstration of both clinical benefit and cost effectiveness will be required in early trial design and planning to obtain regulatory approval.
  • Trial plans will incorporate rules for sub-group endpoints.
  • Non-traditional payer alliances will form to mine population data to determine trial design or indications.
  • Institutions, biotech, and companies will increasingly redefine clinical phases for earlier market entry.
  • Pre-competitive collaborations will be standard to access patient sub-populations for mechanism-focused trials and post-approval tracking will extend clinical and medical team involvement.
Development Pathways

icon

Key Driver of Change

Assurance of “value” for products to reach patient

Pathway to value

Within ten years, value definitions will be used to counteract unsustainable oncology drug costs across developed countries. To gain market access, manufacturers will need to provide payers with clinically meaningful data that documents a significant cancer treatment advance.

  • Traditional clinical endpoints will be replaced with models shifting to patient cost- benefit analysis.
  • Precision cancer therapy will be guided by predictive models of response and risk.
  • Payers will reward innovators that provide meaningful improvement progression-free, stable disease (not just demonstrate a statistical improvement).
  • Pay for performance models will force greater levels of transparency.

We are trying to be an honest broker in helping oncologists and patients make their best-informed treatment decisions based on effectiveness and cost.

Lowell E. Schnipper, MD

Chair of ASCO’s Value in Cancer Care Task Force

icon

Key Driver of Change

Providers’ business model evolution and patient care networks

Pathways to patient satisfaction and clinical outcomes

As hospital-owned and large group practices use informed recommendations from expert scientific or payer organizations to establish clinical pathways for diagnosis and treatment, oncology care approaches will become more defined and standardized.

With cancer survival rates increasing and hospitals aggressively building more integrated networks, a key trend is toward diversified treatment teams to manage episodes of care.

  • After diagnosis, patients will be managed by advanced nurse practitioners and other practice extenders.
  • Robust population databases will allow for better identification and stratification of patient risk.
  • Information technology, including m-health and tele-health, will support patient/clinician interaction and allow remote communication and monitoring.
  • Patients will increasingly share in making cost, QOL, and treatment-effectiveness trade-offs.
Patient Satisfaction

Ready to Learn More About StratMap?

Optivara, Inc. has developed and deployed technology solutions, including StratMap, that help commercial development, medical, R&D and market access teams collaborate and effectively optimize their innovation and R&D investments.

Contact Us